Graft-to-host disease can occur in stem cell transplants when donor immune cells (the graft) recognize the recipient (the host) as a stranger and transplanted immune cells attack the immune system.
Graft-to-host disease may occur in stem cell transplants when donor immune cells (the graft) recognize the recipient (the host) as a stranger and transplanted immune cells then attack host body cells. Graft-to-host disease may also occur after blood transfusion if the blood products used have not been irradiated or treated with an approved pathogen reduction system. Therefore, simultaneous detection of these targets can help to gather more information about these processes. The panel is supplied in a ready-to-use format with individual vials of capture and detection reagents formulated at a concentration of 1X, requiring less pipeting and experimental configuration. It cannot be associated with simplexes or other panels.
ProcartaPlex preconfigured panels are widely tested for combinability, interference and cross-reactivity of analyses to provide the highest level of validation and accuracy. All ProcartaPlex panels are supplied with the reagents necessary to perform the dosage.
ProcartaPlex multiplex panels are available in several formats and can be used on six species (human, mouse, rat, non-human primate, porcine and canine).
Target list [microbead region]: CD30 [34], Granzyme A [74], HGF [46], IL-2R [22], IL-33R (ST2) [35], KRT18 [67], Syndecane [14], TNF-RI [39]
About ProcartaPlex strengths for Luminex platform
ProcartaPlex immunoassays, based on the principles of an ELISA e sandwich, use two highly specific antibodies binding to different epitopes of a protein to simultaneously quantify all target proteins using a Luminex instrument. ProcartaPlex multiplex assays require only 25 µl plasma or serum, or 50 µl cell culture supernatant, and only four hours to obtain the analyzed results.
ProcartaPlex assays use Luminex xMAP (multianalyte profiling) technology to simultaneously detect and quantify up to 80 protein targets in a single sample of 25-50 µl — plasma, serum, cell culture supernatants and other body fluids.
Luminex microbeads in the ProcartaPlex assay are coloured internally with precise proportions of red fluorophores and IR to create unique spectral signatures that can be identified by Luminex xMAP detection systems (e.g. Luminex 200, FLEXMAP 3D and MAGPIX). Like ELISA sandwich, the ProcartaPlex assay uses paired antibody pairs to identify the protein of interest. In a multiplexed assay, each single spectral microbead is marked with antibodies specific to a single target protein and the bound proteins are identified with biotinyl antibodies and streptavidine–R-phycoerythrin (RPE). Conjugation of specific antibodies from a protein to a separate microbead makes it possible to analyze several targets in a single well.
The most significant difference between a ProcartaPlex assay and a ELISA assay is that the ProcartaPlex capture antibody is conjugated with a microbead and is not adsorbed by any of the microplate wells. Thus, ProcartaPlex dosing reagents float freely in the solution. For detection purposes, Luminex 200, for example, contains two lasers: one to distinguish the spectral signature from each microbead and one to quantify the amount of fluorescence of RPE. The latter is proportional to the amount of protein present in the sample. Multiplex ProcartaPlex assays can profile more target proteins using a significantly smaller sample. It takes them as long as they do a traditional ELISA sandwich.